Table 1.
FDA approved ADCs and their characteristics.
| Trade Name | Generic Name | Conjugate | Indication | Target | Year of Approval |
|---|---|---|---|---|---|
| MYLOTARG | Gemtuzumab ozogamicin | Calicheamicin | Hematological | CD33 | 2010/2017 |
| ADCETRIS | Brentuximab vedotin | Monomethyl auristatin E (MMAE) | Hematological | CD30 | 2011 |
| BESPONSA | Inotuzumab ozogamicin | Calicheamicin | Hematological | CD22 | 2017 |
| POLIVY | Polatuzumab vedotin | Monomethyl auristatin E (MMAE) | Hematological | CD79b | 2019 |
| KADCYLA | Trastuzumab emtansine | Myatansinoid (DM1) | Solid tumor | HER2 | 2013 |
| ENHERTU | Trastuzumab deruxtecan | Deruxtecan (Dxd) | Solid tumor | HER2 | 2019 |
| PADCEV | Enfortumab vedotin | Monomethyl auristatin E (MMAE) | Solid tumor | Nectin-4 | 2019 |
| TRODELVY | Sacituzumab govitecan | Govitecan SN-38 | Solid tumor | Trop-2 | 2020 |
| BLENREP | Belantamab mafodotin | Microtubule inhibitor MMAF | Myeloma | BCMA | 2020 |
| ZYNLONTA | Loncastuximab tesirine-lpyl | SG3199 | B-cell lymphoma | CD19 | 2021 |
Taken and modified from Mahmood, I. Clinical Pharmacology of Antibody-Drug Conjugates. Antibodies. 2021; 10: 20. [11].